Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Amyotrophic Lateral Sclerosis ALS Clear all
Completed Not applicable Interventional Results available

Electronic-health Application To Measure Outcomes REmotely Clinical Trial

NCT02418546
View directory record Official record
Conditions
Neurodegenerative Disease, Weight Loss, Amyotrophic Lateral Sclerosis, Parkinson's Disease, Huntington's Disease, Cachexia
Interventions
In-Person Nutritional Counseling by a Registered Dietitian, Nutritional counseling using an e-Health Application
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Jun 10, 2026, 10:19 PM EDT
Recruiting Not applicable Interventional

Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALS

NCT06609213
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Gastrointestinal Intolerance, Enteral Nutrition Therapy
Interventions
Medical Food
Other
Lead sponsor
Andrea Charvet
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jun 10, 2026, 10:19 PM EDT
Terminated Not applicable Interventional

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT03020797
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Perampanel, Placebo Oral Tablet
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Jun 10, 2026, 10:19 PM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen D Pridopidine

NCT04615923
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pridopidine, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Jun 10, 2026, 10:19 PM EDT
Completed No phase listed Observational Results available

A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients

NCT00786032
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
BCI Device
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 79 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
West Haven, Connecticut • Albany, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Jun 10, 2026, 10:19 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

TRIAL READY (Clinical Trial Readiness)

NCT03912987
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis, Progressive Muscular Atrophy
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
3
States / cities
Miami, Florida • Kansas City, Kansas • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jun 10, 2026, 10:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery

NCT01592552
View directory record Official record
Conditions
Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS)
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Sherman Oaks, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Jun 10, 2026, 10:19 PM EDT
Recruiting Phase 2 Interventional

Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial

NCT04244630
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Antioxidants
Combination Product
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Jun 10, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

NCT02450552
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ezogabine, Placebo
Drug
Lead sponsor
Brian Wainger
Other
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jun 10, 2026, 10:19 PM EDT
Recruiting No phase listed Observational

EIM Via the Myolex mScan as an ALS Biomarker

NCT06491732
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Electrical Impedance Myography
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Phoenix, Arizona • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jun 10, 2026, 10:19 PM EDT
Terminated Phase 3 Interventional

Continuation Study for Latozinemab

NCT06111014
View directory record Official record
Conditions
Neurodegenerative Diseases
Interventions
Latozinemab
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jun 10, 2026, 10:19 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

ALS Research Collaborative

NCT06885918
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS (Amyotrophic Lateral Sclerosis), ALS With Frontotemporal Dementia (ALS/FTD), Motor Neuron Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
ALS Therapy Development Institute
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2035
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Jun 10, 2026, 10:19 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD

NCT04220021
View directory record Official record
Conditions
C9orf72 Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia
Interventions
Metformin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jun 10, 2026, 10:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)

NCT01083667
View directory record Official record
Conditions
Familial Amyotrophic Lateral Sclerosis
Interventions
Pyrimethamine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2017 · Synced Jun 10, 2026, 10:19 PM EDT
Completed Phase 3 Interventional Results available

Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS

NCT03505021
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Levosimendan, Placebo for levosimendan
Drug
Lead sponsor
Orion Corporation, Orion Pharma
Industry
Eligibility
18 Years to 120 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
48
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Jun 10, 2026, 10:19 PM EDT
Completed Phase 2Phase 3 Interventional

Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement

NCT00386464
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
noninvasive positive pressure ventilation
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2007 · Synced Jun 10, 2026, 10:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis

NCT00023075
View directory record Official record
Conditions
Primary Lateral Sclerosis, Hereditary Spastic Paraplegia, Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 10:19 PM EDT
Completed No phase listed Observational

Brain Function in Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis

NCT00334516
View directory record Official record
Conditions
Cerebral Cortex Dysfunction
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Jun 10, 2026, 10:19 PM EDT
Terminated Phase 1 Interventional

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)

NCT04288856
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB078
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jun 10, 2026, 10:19 PM EDT
Completed Phase 2 Interventional

Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT00748501
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
SB-509
Drug
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
La Jolla, California • Orange, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Jun 10, 2026, 10:19 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Digital Speech Markers for Monitoring ALS in Spanish Speakers

NCT07341334
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, ALS
Interventions
Not listed
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jun 10, 2026, 10:19 PM EDT
Completed No phase listed Observational

Methodology Study of Novel Outcome Measures to Assess Progression of ALS

NCT02611674
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
16 Years to 85 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Jun 10, 2026, 10:19 PM EDT
Recruiting Phase 2 Interventional

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

NCT07142291
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg)
Drug
Lead sponsor
PhenoNet, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 10, 2026, 10:19 PM EDT
Completed Phase 2 Interventional

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT01281631
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
NP001, Placebo
Drug
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
17
States / cities
Scottsdale, Arizona • Irvine, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Jun 10, 2026, 10:19 PM EDT